Monotherapies involving the use of anti-CTLA-4 and PD-1 monoclonal antibodies have proven efficacy in the treatment of melanoma and non-immunogenic tumors such as non-small lung cell cancer and renal cell carcinoma. This evidence concerns the gene PDCD1 and hereditary clear cell renal cell carcinoma.